BrightGene Bio-Medical Technology Co., Ltd.

BrightGene Bio-Medical Technology Co., Ltd.

Country: China (Mainland)Business Type: Manufacturers

Manufacturer

qq

Products Categories
Contact US
Mr.Kevin Wan
Tel: +86-512-62551801
  • Fax: +86-512-62621799
  • URL: https://en.bright-gene.com/
  • Province/state: Jiangsu
  • City: Suzhou
  • Street:Building C25 - C31, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
  • MaxCard:
Home > Products > 

The China supplier of Micafungin API Cas:208538-73-2

The China supplier of Micafungin API Cas:208538-73-2 CAS NO.208538-73-2

  • Product Details

Keywords

  • Micafungin Sodium
  • echinocandin antifungal drug
  • API purity≥99%

Quick Details

  • ProName: The China supplier of Micafungin API C...
  • CasNo: 208538-73-2
  • Molecular Formula: C56H70N9O23S.Na
  • Appearance: White to off-white solid
  • Application: Anti-fungins;Micafungin is indicated f...
  • DeliveryTime: within two weeks
  • PackAge: According to customer requirements
  • Port: any airport in China
  • ProductionCapacity: 10 Kilogram/Month
  • Purity: NLT 99%
  • Storage: Store in a tight container at a temper...
  • Transportation: transport in coldchain and temperature...
  • LimitNum: 100 Gram
  • Related Substances: 0.10%
  • Residue on Ignition: 0.10%
  • Heavy Metal: 20ppm
  • Valid Period: two years

Superiority

BrightGene Bio-Medical Technology Co., Ltd. is a reserch driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic focus on the regulated market and Cinese market.

We have certifications like EUGMP, CGMP, PMDA and passed FDA inspection in 2013.

The advantages of our Micafungin Sodium

DMF NO. 031449; ASMF ready; commercialized; storerage available

Details

Established in 2001, BrightGene engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market and Chinese market.

We have an excitng and very promising innovative pipeline including immuno-oncological therapeutic agents, orally availabl GLP-1RA peptides for type 2 diabetes, orally avilable oxyntomodulin analog for NASH an novel non-antibody dependent tumor targeting conjugates for brain ad other types of cancer.

In prallel, we have also developed a specil generic pipelin of extremely challenging molecules like Eribulin, Trabectedin, Fondaparinux, Caspofngin and non-biplogica macromolecules such s Ferumoxytol and Ferric pyrophosphate citrate.

Other products of this supplier